NCT05539872Phase 2, phase 3Completed

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Study sponsor: Amphastar Pharmaceuticals, Inc. · AMPH

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-01-29Actual
Enrollment · participants69Actual
Source updated2026-03-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Maximum Serum Insulin Aspart Concentration, CIAmax Measure: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration from time 0 to 12 hours post-dose, AUCIA(0-12h) Measure: Maximum Serum Human Insulin Concentration, CHImax Measure: Area Under the Curve (AUC) of Human Insulin Serum Concentration from time 0 to 12 hours post-dose, AUCHI(0-12h) Measure: Maximum Glucose Infusion Rate, Gmax Measure: Area Under the Curve (AUC) for Glucose Infusion Rate from time 0 to 12 hours post-dose, AUCG(0-12h). After: Measure: Maximum Serum Insulin Aspart Concentration, CIAmax Measure: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration From Time 0 to 12 Hours Post-dose, AUCIA(0-12h) Measure: Maximum Glucose Infusion Rate, Gmax Measure: Area Under the Curve (AUC) for Glucose Infusion Rate From Time 0 to 12 Hours Post-dose, AUCG(0-12h).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview